Regulatory properties of the intestinal microbiome effecting the development and treatment of diabetes.

Current Opinion in Endocrinology, Diabetes, and Obesity
Joann Romano-KeelerDaniel J Moore

Abstract

The microbiome continues to demonstrate an important role in immune and metabolic programming. This review will focus on the mechanistic implications of recent findings for diabetes pathogenesis and treatment. Multiple techniques are developing to specify the microbiome. At the same time, new insights have emerged into local interactions of microbial products with human development. New findings demonstrate that key bacteria and their products result in the programming of diabetes-modulating Th17 and regulatory T lymphocytes within and outside the intestine. The role of the bacterial metagenome in programming human metabolism has also revealed new insights. In turn, these findings suggest a framework in which the microbiome may be modified to change the course of diabetes. The microbiome is a key regulator of metabolism and immunity. Specific bacteria and their secreted products are now known to program Th17 and regulatory T-cell development, which may change the course of diabetes. Bacterial genomics are demonstrating important, modifiable roles of bacterial gene products in metabolism. Further understanding of this symbiotic relationship will provide new avenues for intervention in diabetes.

References

Apr 16, 2005·Science·Paul B EckburgDavid A Relman
Dec 22, 2006·Nature·Ruth E LeyJeffrey I Gordon
Oct 19, 2007·Nature·Peter J TurnbaughJeffrey I Gordon
Mar 10, 2009·Applied and Environmental Microbiology·John SchellenbergFrancis A Plummer
Jun 6, 2009·Obesity·Andreas SchwiertzPhilip D Hardt
Sep 30, 2009·Immunology and Cell Biology·Megan LivingstonMargaret Baird
Mar 20, 2010·Mucosal Immunology·E Wohlfert, Y Belkaid
May 5, 2010·Environmental Microbiology·James I Prosser
Jun 23, 2010·Proceedings of the National Academy of Sciences of the United States of America·June L Round, Sarkis K Mazmanian
Jul 9, 2010·The ISME Journal·Adriana GiongoEric W Triplett
Aug 4, 2010·Archives of Pediatrics & Adolescent Medicine·Marisa A D'AngeliBeth A Mueller
Nov 12, 2010·The New England Journal of Medicine·Mikael KnipUNKNOWN Finnish TRIGR Study Group
Dec 24, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matthias LochnerGérard Eberl
Mar 17, 2011·PloS One·María José GosalbesAndrés Moya
Apr 22, 2011·Nature·Manimozhiyan ArumugamPeer Bork
May 6, 2011·The American Journal of Clinical Nutrition·Reiner JumpertzJonathan Krakoff
Jun 29, 2011·Proceedings of the National Academy of Sciences of the United States of America·Martin A KriegelDiane Mathis
Oct 28, 2011·Science Translational Medicine·Nathan P McNultyJeffrey I Gordon

❮ Previous
Next ❯

Citations

Apr 23, 2014·Clinical Reviews in Allergy & Immunology·Zhiguo XieZhiguang Zhou
Oct 22, 2013·Expert Review of Clinical Immunology·Pjotr BekkeringGer T Rijkers
Jun 20, 2015·Human Vaccines & Immunotherapeutics·Amanda M Jamieson
Feb 16, 2015·Archivum Immunologiae Et Therapiae Experimentalis·Magdalena MuszerMikael Skurnik
Sep 22, 2012·Islets·Nora M ChapmanSteven Tracy
Jun 1, 2016·Frontiers in Immunology·Kumiko Nakada-Tsukui, Tomoyoshi Nozaki
Feb 6, 2020·Frontiers in Genetics·Manvi SharmaTrygve O Tollefsbol
May 19, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Sepideh Zununi VahedYadollah Omidi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.